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Abstract 
Background 
In 2012, the UK Government consulted on standardised packaging (SP) of tobacco products. 
Four transnational tobacco companies (TTCs) submitted large responses opposing SP, 
criticising evidence cited and citing alternative evidence to support their case. We examine 
the problems faced by policy makers assessing large volumes of diverse evidence submitted 
by well-resourced corporate interests to public consultations, and discuss potential 
strategies for evidence management in public health policy making. 
Methods 
We synthesise the results of three UK-based studies. Data were identified from four TTC 
submissions (available online). Assessment criteria for content analyses were developed by 
literature review. Independent second coding of data was used to validate findings (studies 
1 and 2: 100%; study 3: 13%), examine convergence, and resolve interpretation differences. 
Study 1 was a comparative content analysis of quality (independence, peer-review) and 
relevance (subject matter) of 77 research documents cited by TTCs to argue that SP will not 
work, and 37 research documents from a systematic review (SR) of SP. Two-tailed Fisher's 
tests were used to compare datasets. Study 2 was a content analysis of quality, relevance, 
and type (eg, research, opinion, policy) of 92 documents and quotations cited by TTCs to 
argue that SP will have negative, unintended consequences for the UK economy and illicit 
trade. Study 3 was a qualitative interpretive analysis of techniques used by two TTCs to 
undermine evidence of SP's effect on smoking behaviour. 120 purposively selected pages (of 
1037) were analysed using a verification-oriented cross-documentary analysis, comparing 
use of research with originals, and a thematic analysis, informed by principles and 
techniques of constructivist grounded theory—conceptual coding for a-priori and emergent 
themes, constant comparison, discourse sensitivity, and attention to divergent data. 
Findings 
In 1521 pages, the four TTCs cited 143 formal research documents to underpin their 
opposition to SP and made extensive reference to policy documents, quotations, and media 
coverage. In study 1, 12% of TTC research evidence that SP will not work was both relevant 
(addressed SP or tobacco packaging) and fulfilled one or more quality criteria (independent 
of TTCs, published in a peer-reviewed journal, or both), compared with 100% of SR 
evidence. In study 2, 16% of data were both independent and relevant. TTCs offset the 
scarcity of outcome-based evidence on the consequences of SP with industry-commissioned 
research and used independent and industry-connected opinion to inflate the risk of 
unintended consequences. In study 3, TTCs misused published evidence through inaccurate 
reporting, attempted methodological deconstruction through mimicked scientific critique, 
and sought to promote a parallel evidence base to reduce the power and credibility of 
evidence supportive of SP. 
Interpretation 
TTCs used sophisticated, complex, and mutually reinforcing evidential presentation 
strategies to oppose SP. Assessment of submissions and associated evidence represents a 
substantial challenge and cost, causing delay or even abandonment of policies. Two 
strategies could address this. First, implement evidential management processes at 
submission (eg, requiring respondents to record evidential funding sources, conflicts of 
interests, and accuracy of evidential representation). Second, introduce a formal post-
submission evidence assessment framework. Such strategies could reduce costs imposed on 
policy makers by the present requirement to invite and assess evidence from stakeholders. 
They might also reduce the ability of corporate interests to use evidence misrepresentation 
to oppose policy change. The resource advantage of TTCs is a substantial challenge to 
potential reforms. 
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